Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Louis Greer

Podiatrist, Primary Podiatric Medicine Harrisburg, PA Doctor of Podiatric Medicine

NPI 1154380558 CMS profile 187900

4230 Crums Mill Rd, Harrisburg, PA 17112

Open in the dashboard

General payments

$3,384

132 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Louis Greer of Harrisburg, PA is reported in the CMS Open Payments database as having received $3,384 across 132 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Podiatrist, Primary Podiatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $736 28
2024 General $683 24
2023 General $1,040 37
2022 General $379 10
2021 General $164 9
2020 General $179 6
2019 General $203 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Louis Greer
  • Podiatrist, Primary Podiatric Medicine median
  • Middle half of Podiatrist, Primary Podiatric Medicine
  • National median

In program year 2025, general payments to Louis Greer were reported at $736. Among 368 Podiatrist, Primary Podiatric Medicine profiles paid that year, the median was $232 and the middle half received between $88 and $586.

Show as a table
Year Louis Greer Podiatrist, Primary Podiatric Medicine median Middle half National median
2019 $203 $166 $51–$513 $163
2020 $179 $108 $33–$249 $114
2021 $164 $147 $52–$377 $132
2022 $379 $188 $66–$551 $149
2023 $1,040 $195 $70–$509 $160
2024 $683 $209 $59–$508 $164
2025 $736 $232 $88–$586 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $2,104 76 payments
  2. Stryker Corporation $361 9 payments
  3. Cashflow Solutions, LLC $179 6 payments
  4. LifeNet Health $116 3 payments
  5. Pfizer Inc. $111 12 payments
  6. Integra LifeSciences Corporation $60 3 payments
  7. PolyNovo North America LLC $52 2 payments
  8. Acera Surgical, Inc. $52 2 payments
  9. Kowa Pharmaceuticals America, Inc. $48 3 payments
  10. Nevro Corp. $38 2 payments
  11. Other $263 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,384 132 payments
Products named General payments · program years 2019–2025
  1. STRAVIX Extremities & Limb Restoration $403 11 payments
  2. COLLAGENASE SANTYL $310 25 payments
  3. STRAVIX PL $303 5 payments
  4. GRAFIX PL $290 7 payments
  5. STRAVIX MESH $282 8 payments
  6. STRAVIX Extremities & Limb Restoration $240 6 payments
  7. GRAFIX $238 4 payments
  8. BIOSKIN $191 4 payments
  9. PCD-52 737A (US) White $179 6 payments
  10. Lympha Press Optimal Plus(US) BT $179 6 payments
  11. Other $2,271 98 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

508

Median for Podiatry: 160

Drug cost

$25,289

Median for Podiatry: $2,368

Branded share of claims

9.6%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 11 $16,578
Pregabalin Generic 41 $1,694
Bumetanide Generic 83 $1,455
Duloxetine Hcl Generic 105 $1,440
Gentamicin Sulfate Generic 15 $1,301
Terbinafine Hcl Generic 57 $647
Allopurinol Generic 36 $398
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 13 $349
Celecoxib Generic 17 $309
Ammonium Lactate Generic 20 $301

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$28,721

Medicare's payments for the services billed

Medicare patients

127

Average age 74

Services billed

452

70 women, 57 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 45%
Depression 42%
Chronic kidney disease 36%
Heart failure 31%
Ischemic heart disease 31%
Atrial fibrillation 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REGRANEX
  • Smith+Nephew, Inc. $5
$5 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

132 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Primary Podiatric Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record